Blocking type TSH receptor antibodies
TSH receptor (TSHR) autoantibodies (TRAbs) play a key role in the pathogenesis of Graves’ disease. In the majority of patients, TRAbs stimulate thyroid hormone synthesis via activation of the TSHR (stimulating TRAbs, TSHR agonists). In some patients, TRAbs bind to the receptor but do not cause activ...
Gespeichert in:
| Veröffentlicht in: | Autoimmunity highlights Jg. 4; H. 1; S. 11 - 26 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Cham
Springer International Publishing
01.04.2013
Springer Nature B.V |
| Schlagworte: | |
| ISSN: | 2038-0305, 2038-3274 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | TSH receptor (TSHR) autoantibodies (TRAbs) play a key role in the pathogenesis of Graves’ disease. In the majority of patients, TRAbs stimulate thyroid hormone synthesis via activation of the TSHR (stimulating TRAbs, TSHR agonists). In some patients, TRAbs bind to the receptor but do not cause activation (blocking TRAbs, TSHR antagonists). Isolation of human TSHR monoclonal antibodies (MAbs) with either stimulating (M22 and K1-18) or blocking activities (5C9 and K1-70) has been a major advance in studies on the TSHR. The binding characteristics of the blocking MAbs, their interaction with the TSHR and their effect on TSHR constitutive activity are summarised in this review. In addition, the binding arrangement in the crystal structures of the TSHR in complex with the blocking MAb K1-70 and with the stimulating MAb M22 (2.55 Å and 1.9 Å resolution, respectively) are compared. The stimulating effect of M22 and the inhibiting effect of K1-70 on thyroid hormone secretion in vivo is discussed. Furthermore the ability of K1-70 to inhibit the thyroid stimulating activity of M22 in vivo is shown
.
Human MAbs which act as TSHR antagonists are potentially important new therapeutics. For example, in Graves’ disease, K1-70 may well be effective in controlling hyperthyroidism and the eye signs caused by stimulating TRAb. In addition, hyperthyroidism caused by autonomous TSH secretion should be treatable by K1-70, and 5C9 has the potential to control hyperthyroidism associated with TSHR activating mutations. Furthermore, K1-70 has potential applications in thyroid imaging as well as targeted drug delivery to TSHR expressing tissues. |
|---|---|
| AbstractList | TSH receptor (TSHR) autoantibodies (TRAbs) play a key role in the pathogenesis of Graves’ disease. In the majority of patients, TRAbs stimulate thyroid hormone synthesis via activation of the TSHR (stimulating TRAbs, TSHR agonists). In some patients, TRAbs bind to the receptor but do not cause activation (blocking TRAbs, TSHR antagonists). Isolation of human TSHR monoclonal antibodies (MAbs) with either stimulating (M22 and K1-18) or blocking activities (5C9 and K1-70) has been a major advance in studies on the TSHR. The binding characteristics of the blocking MAbs, their interaction with the TSHR and their effect on TSHR constitutive activity are summarised in this review. In addition, the binding arrangement in the crystal structures of the TSHR in complex with the blocking MAb K1-70 and with the stimulating MAb M22 (2.55 Å and 1.9 Å resolution, respectively) are compared. The stimulating effect of M22 and the inhibiting effect of K1-70 on thyroid hormone secretion in vivo is discussed. Furthermore the ability of K1-70 to inhibit the thyroid stimulating activity of M22 in vivo is shown. Human MAbs which act as TSHR antagonists are potentially important new therapeutics. For example, in Graves’ disease, K1-70 may well be effective in controlling hyperthyroidism and the eye signs caused by stimulating TRAb. In addition, hyperthyroidism caused by autonomous TSH secretion should be treatable by K1-70, and 5C9 has the potential to control hyperthyroidism associated with TSHR activating mutations. Furthermore, K1-70 has potential applications in thyroid imaging as well as targeted drug delivery to TSHR expressing tissues. TSH receptor (TSHR) autoantibodies (TRAbs) play a key role in the pathogenesis of Graves' disease. In the majority of patients, TRAbs stimulate thyroid hormone synthesis via activation of the TSHR (stimulating TRAbs, TSHR agonists). In some patients, TRAbs bind to the receptor but do not cause activation (blocking TRAbs, TSHR antagonists). Isolation of human TSHR monoclonal antibodies (MAbs) with either stimulating (M22 and K1-18) or blocking activities (5C9 and K1-70) has been a major advance in studies on the TSHR. The binding characteristics of the blocking MAbs, their interaction with the TSHR and their effect on TSHR constitutive activity are summarised in this review. In addition, the binding arrangement in the crystal structures of the TSHR in complex with the blocking MAb K1-70 and with the stimulating MAb M22 (2.55 Å and 1.9 Å resolution, respectively) are compared. The stimulating effect of M22 and the inhibiting effect of K1-70 on thyroid hormone secretion in vivo is discussed. Furthermore the ability of K1-70 to inhibit the thyroid stimulating activity of M22 in vivo is shown. Human MAbs which act as TSHR antagonists are potentially important new therapeutics. For example, in Graves' disease, K1-70 may well be effective in controlling hyperthyroidism and the eye signs caused by stimulating TRAb. In addition, hyperthyroidism caused by autonomous TSH secretion should be treatable by K1-70, and 5C9 has the potential to control hyperthyroidism associated with TSHR activating mutations. Furthermore, K1-70 has potential applications in thyroid imaging as well as targeted drug delivery to TSHR expressing tissues.TSH receptor (TSHR) autoantibodies (TRAbs) play a key role in the pathogenesis of Graves' disease. In the majority of patients, TRAbs stimulate thyroid hormone synthesis via activation of the TSHR (stimulating TRAbs, TSHR agonists). In some patients, TRAbs bind to the receptor but do not cause activation (blocking TRAbs, TSHR antagonists). Isolation of human TSHR monoclonal antibodies (MAbs) with either stimulating (M22 and K1-18) or blocking activities (5C9 and K1-70) has been a major advance in studies on the TSHR. The binding characteristics of the blocking MAbs, their interaction with the TSHR and their effect on TSHR constitutive activity are summarised in this review. In addition, the binding arrangement in the crystal structures of the TSHR in complex with the blocking MAb K1-70 and with the stimulating MAb M22 (2.55 Å and 1.9 Å resolution, respectively) are compared. The stimulating effect of M22 and the inhibiting effect of K1-70 on thyroid hormone secretion in vivo is discussed. Furthermore the ability of K1-70 to inhibit the thyroid stimulating activity of M22 in vivo is shown. Human MAbs which act as TSHR antagonists are potentially important new therapeutics. For example, in Graves' disease, K1-70 may well be effective in controlling hyperthyroidism and the eye signs caused by stimulating TRAb. In addition, hyperthyroidism caused by autonomous TSH secretion should be treatable by K1-70, and 5C9 has the potential to control hyperthyroidism associated with TSHR activating mutations. Furthermore, K1-70 has potential applications in thyroid imaging as well as targeted drug delivery to TSHR expressing tissues. TSH receptor (TSHR) autoantibodies (TRAbs) play a key role in the pathogenesis of Graves’ disease. In the majority of patients, TRAbs stimulate thyroid hormone synthesis via activation of the TSHR (stimulating TRAbs, TSHR agonists). In some patients, TRAbs bind to the receptor but do not cause activation (blocking TRAbs, TSHR antagonists). Isolation of human TSHR monoclonal antibodies (MAbs) with either stimulating (M22 and K1-18) or blocking activities (5C9 and K1-70) has been a major advance in studies on the TSHR. The binding characteristics of the blocking MAbs, their interaction with the TSHR and their effect on TSHR constitutive activity are summarised in this review. In addition, the binding arrangement in the crystal structures of the TSHR in complex with the blocking MAb K1-70 and with the stimulating MAb M22 (2.55 Å and 1.9 Å resolution, respectively) are compared. The stimulating effect of M22 and the inhibiting effect of K1-70 on thyroid hormone secretion in vivo is discussed. Furthermore the ability of K1-70 to inhibit the thyroid stimulating activity of M22 in vivo is shown . Human MAbs which act as TSHR antagonists are potentially important new therapeutics. For example, in Graves’ disease, K1-70 may well be effective in controlling hyperthyroidism and the eye signs caused by stimulating TRAb. In addition, hyperthyroidism caused by autonomous TSH secretion should be treatable by K1-70, and 5C9 has the potential to control hyperthyroidism associated with TSHR activating mutations. Furthermore, K1-70 has potential applications in thyroid imaging as well as targeted drug delivery to TSHR expressing tissues. TSH receptor (TSHR) autoantibodies (TRAbs) play a key role in the pathogenesis of Graves' disease. In the majority of patients, TRAbs stimulate thyroid hormone synthesis via activation of the TSHR (stimulating TRAbs, TSHR agonists). In some patients, TRAbs bind to the receptor but do not cause activation (blocking TRAbs, TSHR antagonists). Isolation of human TSHR monoclonal antibodies (MAbs) with either stimulating (M22 and K1-18) or blocking activities (5C9 and K1-70) has been a major advance in studies on the TSHR. The binding characteristics of the blocking MAbs, their interaction with the TSHR and their effect on TSHR constitutive activity are summarised in this review. In addition, the binding arrangement in the crystal structures of the TSHR in complex with the blocking MAb K1-70 and with the stimulating MAb M22 (2.55 Å and 1.9 Å resolution, respectively) are compared. The stimulating effect of M22 and the inhibiting effect of K1-70 on thyroid hormone secretion in vivo is discussed. Furthermore the ability of K1-70 to inhibit the thyroid stimulating activity of M22 in vivo is shown. Human MAbs which act as TSHR antagonists are potentially important new therapeutics. For example, in Graves' disease, K1-70 may well be effective in controlling hyperthyroidism and the eye signs caused by stimulating TRAb. In addition, hyperthyroidism caused by autonomous TSH secretion should be treatable by K1-70, and 5C9 has the potential to control hyperthyroidism associated with TSHR activating mutations. Furthermore, K1-70 has potential applications in thyroid imaging as well as targeted drug delivery to TSHR expressing tissues. |
| Author | Furmaniak, Jadwiga Sanders, Jane Rees Smith, Bernard |
| Author_xml | – sequence: 1 givenname: Jadwiga surname: Furmaniak fullname: Furmaniak, Jadwiga organization: FIRS Laboratories, RSR Ltd – sequence: 2 givenname: Jane surname: Sanders fullname: Sanders, Jane organization: FIRS Laboratories, RSR Ltd – sequence: 3 givenname: Bernard surname: Rees Smith fullname: Rees Smith, Bernard email: firs-brs@rsrltd.eclipse.co.uk organization: FIRS Laboratories, RSR Ltd |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26000138$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UU1PAyEUJKbGVu0P8GKaGBMvqw_YD_Zioo1akyYerGfCUqjULVTYmvTfS9PWjybKBd57M8PAHKKWdVYhdILhEgMUVwFTiosEMEkACEvwHuoQoCyhpEhbmzNQyNqoG8IU4qJlHMEBapM8VpiyDjq_rZ18M3bSa5Zz1Rs9D3peSTVvnO8J25jKjY0Kx2hfizqo7mY_Qi_3d6P-IBk-PTz2b4aJTAtokjLXuZZYAKg8I4WuYgPKStJKEc3KLBtrOaZKZhUroxWdy7LSGvBYqirNBKVH6HqtO19UMxXbtvGi5nNvZsIvuROG_55Y88on7oOnlJXA0ihwsRHw7n2hQsNnJkhV18Iqtwgc54yweDXLIvRsBzp1C2_j8zhJISVlmsNK8PSnoy8r2x-MgGINkN6F4JXm0jSiMW5l0NQcA1_Fxddx8RgXX8XFcWTiHeZW_D8OWXNCxNqJ8t-m_yZ9ArM4pZA |
| CitedBy_id | crossref_primary_10_1210_clinem_dgab819 crossref_primary_10_1007_s42000_023_00498_8 crossref_primary_10_5812_ijem_101487 crossref_primary_10_1038_s41574_024_01016_5 crossref_primary_10_1210_clinem_dgae448 crossref_primary_10_3390_ijms21186561 crossref_primary_10_1210_clinem_dgaa646 crossref_primary_10_1055_s_0035_1559648 crossref_primary_10_1016_j_jim_2021_113199 crossref_primary_10_1038_s41572_020_0184_y crossref_primary_10_4049_jimmunol_1601393 crossref_primary_10_1016_j_eprac_2022_07_007 crossref_primary_10_3389_fendo_2020_629925 crossref_primary_10_3389_fimmu_2017_00521 crossref_primary_10_1080_00365513_2019_1658216 crossref_primary_10_4103_tjo_tjo_51_21 crossref_primary_10_5937_jomb0_55873 crossref_primary_10_1155_2018_5794054 crossref_primary_10_3389_fimmu_2017_01845 crossref_primary_10_3390_medicina61030500 crossref_primary_10_1080_14728222_2017_1288215 crossref_primary_10_1089_thy_2015_0447 crossref_primary_10_1210_clinem_dgab824 crossref_primary_10_1515_cclm_2022_0162 crossref_primary_10_1016_j_heliyon_2023_e22468 crossref_primary_10_7759_cureus_40140 crossref_primary_10_1055_a_1130_1573 crossref_primary_10_3389_fphar_2023_1291856 crossref_primary_10_1210_jc_2018_01493 crossref_primary_10_3390_ijms24076187 crossref_primary_10_1186_s40659_025_00618_1 crossref_primary_10_1159_000511538 crossref_primary_10_1186_s13317_019_0121_9 crossref_primary_10_1210_jendso_bvac070 crossref_primary_10_32889_actabioina_182 crossref_primary_10_1530_EJE_18_0678 |
| Cites_doi | 10.1089/105072502321085135 10.1530/eje.1.02295 10.1007/s13317-011-0025-9 10.1111/j.1365-2249.2004.02417.x 10.1210/er.2004-0005 10.1016/S0021-9258(18)55012-2 10.1074/jbc.M008001200 10.1016/S0300-595X(78)80033-4 10.1089/thy.2007.0034 10.1038/nature03206 10.1111/j.1365-2265.2010.03831.x 10.1055/s-0029-1220913 10.4049/jimmunol.160.3.1458 10.1210/me.2004-0231 10.1016/j.clim.2008.09.007 10.1016/S0079-6107(96)00003-X 10.1089/thy.2007.0327 10.1089/thy.2007.0041 10.1210/en.2006-1754 10.1210/me.9.6.725 10.1016/S0950-351X(97)80693-3 10.1080/0891693021000003206 10.1210/mend.16.4.0816 10.1210/er.2002-0020 10.1016/S0140-6736(03)13866-4 10.1089/1050725041692918 10.1089/thy.2006.16.1195 10.1089/thy.2009.0278 10.1016/0968-0004(94)90090-6 10.1016/S0303-7207(98)00207-X 10.3109/08916939309077350 10.1089/105072502321085144 10.1074/jbc.M109.005710 10.1210/en.2008-0207 10.1677/JME-08-0152 10.1210/er.19.6.673 10.1016/j.cbpa.2010.06.170 10.4049/jimmunol.176.8.5084 10.1136/bjo.2004.050807 10.1038/nrd984 10.1001/jama.1943.02840190008003 10.1172/JCI119687 10.1089/thy.2004.14.830 10.1210/jcem.81.9.8784059 10.1074/jbc.M800449200 10.1530/eje.0.1460163 10.1002/ddr.10346 10.1093/emboj/21.4.504 10.1089/thy.1998.8.693 10.1136/bmj.332.7554.1369 10.1111/j.1365-2265.2004.02028.x 10.1210/endo.141.9.7790 10.1056/NEJMcp0801880 10.1677/jme.0.0200233 10.1677/JME-08-0040 10.1016/B978-0-12-381296-4.00022-1 10.1089/thy.2005.15.746 10.1089/thy.2000.10.1051 10.1111/j.1365-2249.2010.04301.x 10.1080/02841860600979013 10.1046/j.1365-2249.1998.00622.x 10.1089/thy.2004.14.991 10.1089/thy.2007.0239 10.1172/JCI0216991 10.1089/thy.2011.0147 10.1089/10507250360731569 10.1530/JME-10-0127 10.1210/edrv-17-6-610 10.1089/thy.2005.15.672 10.1677/JOE-09-0262 10.1016/j.ando.2011.03.006 10.1210/edrv-9-1-106 10.1089/10507250050137761 10.1016/S0006-291X(02)02762-6 10.1210/jc.2003-031554 10.1038/365649a0 10.1056/NEJMra042972 |
| ContentType | Journal Article |
| Copyright | Springer-Verlag 2012 Springer-Verlag 2012. |
| Copyright_xml | – notice: Springer-Verlag 2012 – notice: Springer-Verlag 2012. |
| DBID | AAYXX CITATION NPM 8FE 8FH ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ HCIFZ LK8 M7P PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1007/s13317-012-0028-1 |
| DatabaseName | CrossRef PubMed ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central ProQuest Central Student SciTech Premium Collection (via ProQuest) Biological Sciences Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Biological Science Collection ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection Biological Science Database ProQuest SciTech Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Academic UKI Edition Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: PIMPY name: ProQuest Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2038-3274 |
| EndPage | 26 |
| ExternalDocumentID | PMC4389084 26000138 10_1007_s13317_012_0028_1 |
| Genre | Journal Article Review |
| GroupedDBID | --- 06D 0R~ 0VY 2JY 2VQ 30V 4.4 408 409 53G 67N 8FE 8FH 8TC AAIAL AAYZH ABBXA ABDBF ABFSG ACGFS ACPRK ACSTC ACUHS ADBBV ADRAZ ADUKV AEZWR AFBBN AFHIU AFKRA AFWTZ AHBYD AHSBF AHWEU AHYZX AIXLP AKMHD ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAPOH BAWUL BBNVY BENPR BFQNJ BGNMA BHPHI BMC C6C CCPQU DIK EBLON EBS EJD G-Y G-Z GQ7 GQ8 H13 HCIFZ HF~ HMJXF HYE HZ~ I0C IAO ITC IZIGR J0Z KOV KQ8 LK8 M48 M4Y M7P NU0 O9- O93 O9I OK1 PGMZT PHGZM PHGZT PIMPY PQGLB PUEGO QOS R9I ROL RPM RSV S1Z S27 S3A S3B SBL SHX SOJ T13 U2A WK8 Z45 ~A9 AAYXX AFFHD CITATION NPM ABUWG AZQEC DWQXO GNUQQ PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c470t-96f6fc1a00e6527fb96f09bc3be2f8955dfcd3ec5b89927f6c9bff01dceb45a33 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 37 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000218941200002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2038-0305 |
| IngestDate | Tue Nov 04 01:57:59 EST 2025 Thu Oct 02 06:50:40 EDT 2025 Fri Jul 25 11:07:03 EDT 2025 Mon Jul 21 06:03:38 EDT 2025 Sat Nov 29 02:51:49 EST 2025 Tue Nov 18 21:30:43 EST 2025 Sat Sep 06 07:28:20 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Autoimmunity Graves’ disease Thyroid stimulating autoantibody Thyroid blocking autoantibody TSH receptor |
| Language | English |
| License | http://www.springer.com/tdm |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c470t-96f6fc1a00e6527fb96f09bc3be2f8955dfcd3ec5b89927f6c9bff01dceb45a33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2404294604?pq-origsite=%requestingapplication% |
| PMID | 26000138 |
| PQID | 2404294604 |
| PQPubID | 2043794 |
| PageCount | 16 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4389084 proquest_miscellaneous_1682892785 proquest_journals_2404294604 pubmed_primary_26000138 crossref_citationtrail_10_1007_s13317_012_0028_1 crossref_primary_10_1007_s13317_012_0028_1 springer_journals_10_1007_s13317_012_0028_1 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-04-01 |
| PublicationDateYYYYMMDD | 2013-04-01 |
| PublicationDate_xml | – month: 04 year: 2013 text: 2013-04-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Cham |
| PublicationPlace_xml | – name: Cham – name: England – name: Heidelberg |
| PublicationTitle | Autoimmunity highlights |
| PublicationTitleAbbrev | Autoimmun Highlights |
| PublicationTitleAlternate | Auto Immun Highlights |
| PublicationYear | 2013 |
| Publisher | Springer International Publishing Springer Nature B.V |
| Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V |
| References | M Luster (28_CR74) 2006; 45 B Rees Smith (28_CR26) 2009; 41 R Núñez Miguel (28_CR53) 2009; 42 S Hamidi (28_CR47) 2011; 21 K Krohn (28_CR35) 2005; 26 B Rees Smith (28_CR4) 2007; 17 B Rapoport (28_CR70) 2000; 10 J Sanders (28_CR25) 2008; 18 28_CR78 S Mueller (28_CR41) 2008; 283 SC Alley (28_CR75) 2010; 14 CR Chen (28_CR30) 2007; 148 S Costagliola (28_CR10) 2004; 18 SG Buchanan (28_CR49) 1996; 65 J Sanders (28_CR77) 2008; 18 J Gilbert (28_CR11) 2006; 176 SM McLachlan (28_CR6) 2004; 61 J Sanders (28_CR7) 2002; 12 H Vlase (28_CR21) 1998; 113 P Kopp (28_CR36) 1997; 100 J Parma (28_CR37) 1995; 9 C-R Chen (28_CR45) 2001; 276 S Costagliola (28_CR15) 2002; 21 WB Minich (28_CR18) 2004; 136 P Sanders (28_CR28) 2011; 46 TF Davies (28_CR16) 1998; 8 R Volpé (28_CR64) 1978; 7 Y Oda (28_CR19) 1998; 20 S Mueller (28_CR42) 2009; 284 R Núñez Miguel (28_CR51) 2005; 15 J Sanders (28_CR39) 2006; 16 C Lenzner (28_CR17) 2003; 13 DS Cooper (28_CR60) 2005; 352 J Sanders (28_CR23) 2004; 14 I Ueki (28_CR69) 2011; 163 B Kobe (28_CR48) 1994; 19 A Boschi (28_CR57) 2005; 89 M Evans (28_CR27) 2010; 73 T Ando (28_CR8) 2002; 110 Y Oda (28_CR20) 2000; 10 M Sequeira (28_CR56) 2002; 146 CR Chen (28_CR31) 2008; 149 OH Brekke (28_CR72) 2003; 2 SM McLachlan (28_CR5) 1996; 81 PS Shepherd (28_CR13) 1999; 149 VK Vlaeminck-Guillem (28_CR33) 2002; 16 EN Pearce (28_CR61) 2006; 332 J Sanders (28_CR22) 2003; 362 GR Williams (28_CR59) 2011; 72 J Jeffreys (28_CR14) 2002; 12 P Beck-Peccoz (28_CR71) 1996; 17 D Fassi El (28_CR68) 2009; 130 J Sanders (28_CR34) 1997; 11 M Horimoto (28_CR54) 1993; 14 R Núñez Miguel (28_CR50) 2004; 14 S Costagliola (28_CR55) 1998; 160 S Costagliola (28_CR9) 2002; 299 GD Chazenbalk (28_CR46) 2004; 89 P Laurberg (28_CR65) 2006; 155 LK Roskos (28_CR73) 2004; 61 B Rees Smith (28_CR3) 2004; 14 BS Prabhakar (28_CR66) 2003; 24 B Rapoport (28_CR2) 1998; 19 S Kosugi (28_CR40) 1991; 266 EB Astwood (28_CR63) 1943; 122 J Sanders (28_CR12) 2005; 15 J Sanders (28_CR29) 2010; 485 J Sanders (28_CR24) 2007; 17 M Zhang (28_CR32) 2000; 141 A Lloyd de (28_CR58) 2010; 204 B Rees Smith (28_CR1) 1988; 9 J Sanders (28_CR43) 2007; 17 R Núñez Miguel (28_CR52) 2008; 41 S Kumar (28_CR67) 2010; 20 J Parma (28_CR38) 1993; 365 QR Fan (28_CR44) 2005; 433 N Hayakawa (28_CR76) 2002; 35 GA Brent (28_CR62) 2008; 358 |
| References_xml | – volume: 12 start-page: 1043 year: 2002 ident: 28_CR7 publication-title: Thyroid doi: 10.1089/105072502321085135 – volume: 155 start-page: 783 year: 2006 ident: 28_CR65 publication-title: Eur J Endocrinol doi: 10.1530/eje.1.02295 – ident: 28_CR78 doi: 10.1007/s13317-011-0025-9 – volume: 136 start-page: 129 year: 2004 ident: 28_CR18 publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.2004.02417.x – volume: 26 start-page: 504 year: 2005 ident: 28_CR35 publication-title: Endocr Rev doi: 10.1210/er.2004-0005 – volume: 266 start-page: 19413 year: 1991 ident: 28_CR40 publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)55012-2 – volume: 276 start-page: 14767 year: 2001 ident: 28_CR45 publication-title: J Biol Chem doi: 10.1074/jbc.M008001200 – volume: 7 start-page: 3 year: 1978 ident: 28_CR64 publication-title: Clin Endocr Metab doi: 10.1016/S0300-595X(78)80033-4 – volume: 17 start-page: 395 year: 2007 ident: 28_CR24 publication-title: Thyroid doi: 10.1089/thy.2007.0034 – volume: 433 start-page: 269 year: 2005 ident: 28_CR44 publication-title: Nature doi: 10.1038/nature03206 – volume: 73 start-page: 404 year: 2010 ident: 28_CR27 publication-title: Clin Endocrinol doi: 10.1111/j.1365-2265.2010.03831.x – volume: 41 start-page: 448 year: 2009 ident: 28_CR26 publication-title: Hormon Metab Res doi: 10.1055/s-0029-1220913 – volume: 160 start-page: 1458 year: 1998 ident: 28_CR55 publication-title: J Immunol doi: 10.4049/jimmunol.160.3.1458 – volume: 18 start-page: 3020 year: 2004 ident: 28_CR10 publication-title: Mol Endocrinol doi: 10.1210/me.2004-0231 – volume: 130 start-page: 252 year: 2009 ident: 28_CR68 publication-title: Clin Immunol doi: 10.1016/j.clim.2008.09.007 – volume: 65 start-page: 1 year: 1996 ident: 28_CR49 publication-title: Prog Biophys Mol Biol doi: 10.1016/S0079-6107(96)00003-X – volume: 18 start-page: 735 year: 2008 ident: 28_CR25 publication-title: Thyroid doi: 10.1089/thy.2007.0327 – volume: 17 start-page: 699 year: 2007 ident: 28_CR43 publication-title: Thyroid doi: 10.1089/thy.2007.0041 – volume: 148 start-page: 2375 year: 2007 ident: 28_CR30 publication-title: Endocrinology doi: 10.1210/en.2006-1754 – volume: 18 start-page: 735 issue: 7 year: 2008 ident: 28_CR77 publication-title: Thyroid doi: 10.1089/thy.2007.0327 – volume: 9 start-page: 725 year: 1995 ident: 28_CR37 publication-title: Mol Endocrinol doi: 10.1210/me.9.6.725 – volume: 11 start-page: 451 year: 1997 ident: 28_CR34 publication-title: Baillière’s Clin Endocr Metab doi: 10.1016/S0950-351X(97)80693-3 – volume: 35 start-page: 343 year: 2002 ident: 28_CR76 publication-title: Autoimmunity doi: 10.1080/0891693021000003206 – volume: 16 start-page: 736 year: 2002 ident: 28_CR33 publication-title: Mol Endocrinol doi: 10.1210/mend.16.4.0816 – volume: 24 start-page: 802 year: 2003 ident: 28_CR66 publication-title: Endocr Rev doi: 10.1210/er.2002-0020 – volume: 362 start-page: 126 year: 2003 ident: 28_CR22 publication-title: Lancet doi: 10.1016/S0140-6736(03)13866-4 – volume: 14 start-page: 560 year: 2004 ident: 28_CR23 publication-title: Thyroid doi: 10.1089/1050725041692918 – volume: 16 start-page: 1195 year: 2006 ident: 28_CR39 publication-title: Thyroid doi: 10.1089/thy.2006.16.1195 – volume: 20 start-page: 59 year: 2010 ident: 28_CR67 publication-title: Thyroid doi: 10.1089/thy.2009.0278 – volume: 19 start-page: 415 year: 1994 ident: 28_CR48 publication-title: Trends Biochem Sci doi: 10.1016/0968-0004(94)90090-6 – volume: 149 start-page: 197 year: 1999 ident: 28_CR13 publication-title: Mol Cell Endocrinol doi: 10.1016/S0303-7207(98)00207-X – volume: 14 start-page: 1 year: 1993 ident: 28_CR54 publication-title: Autoimmunity doi: 10.3109/08916939309077350 – volume: 12 start-page: 1051 year: 2002 ident: 28_CR14 publication-title: Thyroid doi: 10.1089/105072502321085144 – volume: 284 start-page: 16317 year: 2009 ident: 28_CR42 publication-title: J Biol Chem doi: 10.1074/jbc.M109.005710 – volume: 149 start-page: 3427 year: 2008 ident: 28_CR31 publication-title: Endocrinology doi: 10.1210/en.2008-0207 – volume: 42 start-page: 381 year: 2009 ident: 28_CR53 publication-title: J Mol Endocrinol doi: 10.1677/JME-08-0152 – volume: 19 start-page: 673 year: 1998 ident: 28_CR2 publication-title: Endocr Rev doi: 10.1210/er.19.6.673 – volume: 14 start-page: 529 year: 2010 ident: 28_CR75 publication-title: Curr Opin Chem Biol doi: 10.1016/j.cbpa.2010.06.170 – volume: 176 start-page: 5084 year: 2006 ident: 28_CR11 publication-title: J Immunol doi: 10.4049/jimmunol.176.8.5084 – volume: 89 start-page: 724 year: 2005 ident: 28_CR57 publication-title: Br J Ophthalmol doi: 10.1136/bjo.2004.050807 – volume: 2 start-page: 52 year: 2003 ident: 28_CR72 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd984 – volume: 122 start-page: 78 year: 1943 ident: 28_CR63 publication-title: J Am Med Assoc doi: 10.1001/jama.1943.02840190008003 – volume: 100 start-page: 1634 year: 1997 ident: 28_CR36 publication-title: J Clin Investig doi: 10.1172/JCI119687 – volume: 14 start-page: 830 year: 2004 ident: 28_CR3 publication-title: Thyroid doi: 10.1089/thy.2004.14.830 – volume: 81 start-page: 3152 year: 1996 ident: 28_CR5 publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem.81.9.8784059 – volume: 283 start-page: 18048 year: 2008 ident: 28_CR41 publication-title: J Biol Chem doi: 10.1074/jbc.M800449200 – volume: 146 start-page: 163 year: 2002 ident: 28_CR56 publication-title: Eur J Endocrinol doi: 10.1530/eje.0.1460163 – volume: 61 start-page: 108 year: 2004 ident: 28_CR73 publication-title: Drug Dev Res doi: 10.1002/ddr.10346 – volume: 21 start-page: 504 year: 2002 ident: 28_CR15 publication-title: EMBO J doi: 10.1093/emboj/21.4.504 – volume: 8 start-page: 693 year: 1998 ident: 28_CR16 publication-title: Thyroid doi: 10.1089/thy.1998.8.693 – volume: 332 start-page: 1369 year: 2006 ident: 28_CR61 publication-title: Br Med J doi: 10.1136/bmj.332.7554.1369 – volume: 61 start-page: 10 year: 2004 ident: 28_CR6 publication-title: Clin Endocrinol doi: 10.1111/j.1365-2265.2004.02028.x – volume: 141 start-page: 3514 year: 2000 ident: 28_CR32 publication-title: Endocrinology doi: 10.1210/endo.141.9.7790 – volume: 358 start-page: 2594 year: 2008 ident: 28_CR62 publication-title: N Engl J Med doi: 10.1056/NEJMcp0801880 – volume: 20 start-page: 233 year: 1998 ident: 28_CR19 publication-title: J Mol Endocrinol doi: 10.1677/jme.0.0200233 – volume: 41 start-page: 145 year: 2008 ident: 28_CR52 publication-title: J Mol Endocrinol doi: 10.1677/JME-08-0040 – volume: 485 start-page: 393 year: 2010 ident: 28_CR29 publication-title: Methods Enzymol doi: 10.1016/B978-0-12-381296-4.00022-1 – volume: 15 start-page: 746 year: 2005 ident: 28_CR51 publication-title: Thyroid doi: 10.1089/thy.2005.15.746 – volume: 10 start-page: 1051 year: 2000 ident: 28_CR20 publication-title: Thyroid doi: 10.1089/thy.2000.10.1051 – volume: 163 start-page: 309 year: 2011 ident: 28_CR69 publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.2010.04301.x – volume: 45 start-page: 1018 year: 2006 ident: 28_CR74 publication-title: Acta Oncol doi: 10.1080/02841860600979013 – volume: 113 start-page: 111 year: 1998 ident: 28_CR21 publication-title: Clin Exp Immunol doi: 10.1046/j.1365-2249.1998.00622.x – volume: 14 start-page: 991 year: 2004 ident: 28_CR50 publication-title: Thyroid doi: 10.1089/thy.2004.14.991 – volume: 17 start-page: 923 year: 2007 ident: 28_CR4 publication-title: Thyroid doi: 10.1089/thy.2007.0239 – volume: 110 start-page: 1667 year: 2002 ident: 28_CR8 publication-title: J Clin Investig doi: 10.1172/JCI0216991 – volume: 21 start-page: 1013 year: 2011 ident: 28_CR47 publication-title: Thyroid doi: 10.1089/thy.2011.0147 – volume: 13 start-page: 1153 year: 2003 ident: 28_CR17 publication-title: Thyroid doi: 10.1089/10507250360731569 – volume: 46 start-page: 81 year: 2011 ident: 28_CR28 publication-title: J Mol Endocrinol doi: 10.1530/JME-10-0127 – volume: 17 start-page: 610 year: 1996 ident: 28_CR71 publication-title: Endocr Rev doi: 10.1210/edrv-17-6-610 – volume: 15 start-page: 672 year: 2005 ident: 28_CR12 publication-title: Thyroid doi: 10.1089/thy.2005.15.672 – volume: 204 start-page: 13 year: 2010 ident: 28_CR58 publication-title: J Endocrinol doi: 10.1677/JOE-09-0262 – volume: 72 start-page: 68 year: 2011 ident: 28_CR59 publication-title: Ann Endocrinol doi: 10.1016/j.ando.2011.03.006 – volume: 9 start-page: 106 year: 1988 ident: 28_CR1 publication-title: Endocr Rev doi: 10.1210/edrv-9-1-106 – volume: 10 start-page: 685 year: 2000 ident: 28_CR70 publication-title: Thyroid doi: 10.1089/10507250050137761 – volume: 299 start-page: 891 year: 2002 ident: 28_CR9 publication-title: Biochem Biophys Res Commun doi: 10.1016/S0006-291X(02)02762-6 – volume: 89 start-page: 1788 year: 2004 ident: 28_CR46 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2003-031554 – volume: 365 start-page: 649 year: 1993 ident: 28_CR38 publication-title: Nature doi: 10.1038/365649a0 – volume: 352 start-page: 905 year: 2005 ident: 28_CR60 publication-title: N Engl J Med doi: 10.1056/NEJMra042972 |
| SSID | ssj0000392740 |
| Score | 2.1088052 |
| SecondaryResourceType | review_article |
| Snippet | TSH receptor (TSHR) autoantibodies (TRAbs) play a key role in the pathogenesis of Graves’ disease. In the majority of patients, TRAbs stimulate thyroid hormone... TSH receptor (TSHR) autoantibodies (TRAbs) play a key role in the pathogenesis of Graves' disease. In the majority of patients, TRAbs stimulate thyroid hormone... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 11 |
| SubjectTerms | Antagonists Autoantibodies Biomedical and Life Sciences Biomedicine Drug delivery Graves' disease Hyperthyroidism Immunology Monoclonal antibodies Review Review Article Secretion Thyroid Thyroid gland Thyroid-stimulating hormone Thyroid-stimulating hormone receptors |
| SummonAdditionalLinks | – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3ZSsNAcBAP8MX7iFaJoC9KYJPs5nhUsfSpiK3St7AnFiQtPQT_3tk0SalVQV8zm2xmZ3fnngG4TBUzRkfCkzIxHhW-8jgz3FOcKF8y6itOi2YTcbud9HrpY5nHPa6i3SuXZHFTz5PdQuR1qPoGXmESQpVnDbldYvs1PHVeasMKQY4fF4mQAQlt-hhhlTfzu68s8qMlIXM5VvKLw7TgQ83tf2GwA1ul2OnezvbJLqzofA82Zo0oP_bh6g55mjWau9Yk63Y7LRdvQj1EhdzFpe-LgQ02PIDn5kP3vuWVDRQ8SWMy8dLIREb6nBAdsSA2Ah-QVMhQ6MAkKWPKSBVqyQRqXQiPZCqMIT4iKyjjYXgIq_kg18fg2rKJWuko4CqlknJuEsJNmKAAEEgqYgdItYyZLKuL2yYXb9m8LrLFPkPsM4t95jtwXb8ynJXW-G1wo6JNVp6ycYbSCLJTGhHqwEUNxvNhnR4814PpOPMjq1MGccIcOJqRsp7NFue3nloH4gUi1wNs7e1FSN5_LWpw26bxJMF5bypSz3_rRyRO_jT6FDaDoveGDRNqwOpkNNVnsC7fJ_3x6LzY9J-ziPtm priority: 102 providerName: Springer Nature |
| Title | Blocking type TSH receptor antibodies |
| URI | https://link.springer.com/article/10.1007/s13317-012-0028-1 https://www.ncbi.nlm.nih.gov/pubmed/26000138 https://www.proquest.com/docview/2404294604 https://www.proquest.com/docview/1682892785 https://pubmed.ncbi.nlm.nih.gov/PMC4389084 |
| Volume | 4 |
| WOSCitedRecordID | wos000218941200002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2038-3274 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0000392740 issn: 2038-0305 databaseCode: M7P dateStart: 20100501 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2038-3274 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0000392740 issn: 2038-0305 databaseCode: BENPR dateStart: 20100501 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content Database customDbUrl: eissn: 2038-3274 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0000392740 issn: 2038-0305 databaseCode: PIMPY dateStart: 20100501 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 2038-3274 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0000392740 issn: 2038-0305 databaseCode: RSV dateStart: 20100501 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RFqReKM8SWlZBggsownHsPE6oRa3KgVXUFrScIj_FSii7dLdI_HtmvElW24peOCZ25IzHnvE8PB_Am8pK712uE2NKnwid2kRJrxKrmE2NFKlVIoBNFONxOZlUdedwW3Rplb1MDILazgz5yD-g5kHRKXImPs5_JYQaRdHVDkJjC3aoSgIPqXv14GNhqPyLcCeSs4xukjHZBzbD7bkMlSfa0jwJPqZ0UzXdOm_eTpu8ETsNKul073-JeQQPu8NofLRaPY_hnmufwIMVPOWfp_D2GDUdudJjctTGlxdnMcpHN0czPUaGTPWMUhCfwdfTk8tPZ0kHq5AYUbBlUuU-9yZVjLlc8sJrfMEqbTLtuC8rKa03NnNGarTFsD03lfaepUi3FlJl2XPYbmetewExFVN01uVc2UoYoZQvmfJZiccCboQuImD9jDamqzlO0Bc_m3W1ZGJCg0xoiAlNGsG74ZP5quDGXZ0P-_ltur23aNaTG8HroRl3DYVCVOtm14smzcnS5EUpI9hfcXUYjUr2U_w2gmKD30MHqsi92dJOf4TK3AQlz0oc932_Mta_9U8iXt5NxAHs8gDBQdlCh7C9vLp2r-C--b2cLq5GsFVMyhHsHJ-M6_NRWP74VH_-Un_Hp_OLb38Bk1cLdQ |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Zb9QwEB5VWxC8cB-BAkGiL6AIx7FzPCDEVe2q7WolFqk8uT7Vlapk2d2C-qf4jXhyrZaKvvWB1ziR7cx4ZjzXB_CqMNw5m6pI69xFTMUmktzJyEhiYs1ZbCSrwSay8Tg_OiomW_C7q4XBtMpOJtaC2lQafeRvvebxopOlhL2f_4gQNQqjqx2ERsMW-_b8l7-yLd-NPnv67lK692X6aRi1qAKRZhlZRUXqUqdjSYhNOc2c8g9IoXSiLHV5wblx2iRWc-WvIn481YVyjsRGW8W4RAeoF_nbDJl9ANuT0eHke-_VId7cyOoqTEoSrF0jvAul1vV6iVfX_vZOo9qrFW8qwwsW7sVEzb-itbUS3Lv9v_2-O3CrNbfDD835uAtbtrwH1xsAzvP7sPvR63IMFoToig6nX4eh1wB2vqoWoWe5maowyfIBfLuSNT6EQVmV9jGE2C7SGptSaQqmmZQuJ9IluTd8qGYqC4B0FBS67aqO4B6nYt0PGokuPNEFEl3EAbzuP5k3LUUue3mno6dopctSrIkZwMt-2MsFDPbI0lZnSxGneJemWc4DeNRwUT8bghJghDqAbIO_-hew5_jmSDk7qXuPM2_gktzP-6bjxPWy_rmJJ5dv4gXcGE4PD8TBaLz_FG7SGnAEc6N2YLBanNlncE3_XM2Wi-ftcQvh-KpZ9A9dS2fu |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS9xAEB-K1uKLbbVq1NYU2pdKcJPs5uOxtj2UlkPQFt-W_cQDyR3eKfjfO5Ov49QKpa_ZTTazk818_wbgU2mF9y7TkTGFj7iObaSEV5FVzMZG8NgqXjebyIfD4uKiPG37nE67bPcuJNnUNBBKUzU7nFh_OC98S1HuoRmcRLV7CM2fZU559GSun_3pnSwMpX9eF0UmLKVSMia6yOZTT1mUTY8Uzsd5kw-Cp7VMGrz-b2rewFqrjoZfm-_nLbxw1TqsNA0q7zbg8xHKOnKmh-SqDc_PjkP8Q7oJGuohsmSkx5SE-A5-D36cfzuO2sYKkeE5m0Vl5jNvYsWYy0SSe40XWKlNql3ii1II641NnREarTEcz0ypvWcxEq65UGm6CUvVuHLbEBKcorMuS5QtueFK-YIpnxaoGCSG6zwA1m2pNC3qODW_uJJzvGSiXiL1kqiXcQBf-lsmDeTGc5P3Oj7J9vRNJWopKGZ5xngAH_thPDcUDFGVG99MZZyRrZnkhQhgq2FrvxqB9lMEN4B8geH9BMLkXhypRpc1Njc1k2cFrnvQsX3-Wn8lYuefZu_Dq9PvA_nrZPhzF1aTuj0HZRLtwdLs-sa9h5fmdjaaXn-oz8I9Dh8HPQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Blocking+type+TSH+receptor+antibodies&rft.jtitle=Autoimmunity+highlights&rft.au=Furmaniak%2C+Jadwiga&rft.au=Sanders%2C+Jane&rft.au=Rees+Smith%2C+Bernard&rft.date=2013-04-01&rft.issn=2038-0305&rft.volume=4&rft.issue=1&rft.spage=11&rft_id=info:doi/10.1007%2Fs13317-012-0028-1&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2038-0305&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2038-0305&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2038-0305&client=summon |